BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32747742)

  • 1. Dexamethasone nanomedicines for COVID-19.
    Lammers T; Sofias AM; van der Meel R; Schiffelers R; Storm G; Tacke F; Koschmieder S; Brümmendorf TH; Kiessling F; Metselaar JM
    Nat Nanotechnol; 2020 Aug; 15(8):622-624. PubMed ID: 32747742
    [No Abstract]   [Full Text] [Related]  

  • 2. Audio Interview: Tocilizumab and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
    [No Abstract]   [Full Text] [Related]  

  • 3. The potential role of nanomedicine on COVID-19 therapeutics.
    Mainardes RM; Diedrich C
    Ther Deliv; 2020 Jul; 11(7):411-414. PubMed ID: 32594863
    [No Abstract]   [Full Text] [Related]  

  • 4. Sofosbuvir for COVID-19 infection: A potential candidate.
    Gupta R; Dhamija P
    Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins in coronavirus outbreak: It's time for experimental and clinical studies.
    Bifulco M; Gazzerro P
    Pharmacol Res; 2020 Jun; 156():104803. PubMed ID: 32289478
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 update: Covid-19-associated coagulopathy.
    Becker RC
    J Thromb Thrombolysis; 2020 Jul; 50(1):54-67. PubMed ID: 32415579
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the type of diabetes treatment relevant to outcome of COVID-19?
    Bloomgarden Z
    J Diabetes; 2020 Jul; 12(7):486-487. PubMed ID: 32353193
    [No Abstract]   [Full Text] [Related]  

  • 8. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
    Sarma P; Prajapat M; Avti P; Kaur H; Kumar S; Medhi B
    Indian J Pharmacol; 2020; 52(1):1-5. PubMed ID: 32201439
    [No Abstract]   [Full Text] [Related]  

  • 10. Boosting the arsenal against COVID-19 through computational drug repurposing.
    Ciliberto G; Cardone L
    Drug Discov Today; 2020 Jun; 25(6):946-948. PubMed ID: 32304645
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 infection and the cardiovascular system.
    Romeo F; Calcaterra G; Barilla F; Mehta JL
    J Cardiovasc Med (Hagerstown); 2020 Jun; 21(6):403-405. PubMed ID: 32324641
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
    Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
    Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
    [No Abstract]   [Full Text] [Related]  

  • 13. Audio Interview: Dexamethasone and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Jul; 383(4):e52. PubMed ID: 32706553
    [No Abstract]   [Full Text] [Related]  

  • 14. Dexamethasone in the management of covid -19.
    Johnson RM; Vinetz JM
    BMJ; 2020 Jul; 370():m2648. PubMed ID: 32620554
    [No Abstract]   [Full Text] [Related]  

  • 15. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
    DiNicolantonio JJ; Barroso J; McCarty M
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
    [No Abstract]   [Full Text] [Related]  

  • 16. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 17. Dexamethasone: A boon for critically ill COVID-19 patients?
    Patel SK; Saikumar G; Rana J; Dhama J; Yatoo MI; Tiwari R; Rodríguez-Morales AJ; Dhama K
    Travel Med Infect Dis; 2020; 37():101844. PubMed ID: 32791213
    [No Abstract]   [Full Text] [Related]  

  • 18. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Mar; 16(687):606-607. PubMed ID: 32216186
    [No Abstract]   [Full Text] [Related]  

  • 20. Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.
    Nauka PC; Oran E; Chekuri S
    Thromb Res; 2020 Aug; 192():27-28. PubMed ID: 32419710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.